SUMMARY Twenty five patients with chronic congestive cardiac failure had enalapril (n = 13) or placebo (n = 12) added to their existing regimen of digoxin and frusemide in a randomised double blind trial. Four hours after the first 5 mg dose, the enalapril group showed significant falls in blood pressure, heart rate, and concentrations of plasma angiotensin II, angiotensin converting enzyme, and noradrenaline. During the 12 week trial heart failure became worse in one enalapril treated patient (8%) and in seven placebo treated patients (58%). There were no significant changes in cardiac ejection fraction or exercise duration in either group. Plasma noradrenaline response to graded exercise and maximum exercise rate-pressure product were significantly reduced after four and 12 weeks of active treatment but unchanged with placebo treatment. There was a sustained increase in plasma potassium and a slight rise in plasma creatinine in the enalapril group. Plasma concentrations of the active drug, enalaprilate, were dose related and log enalaprilate correlated significantly with percentage of plasma angiotensin converting enzyme activity (r =0 66). Enalapril was well tolerated and produced no adverse effects. The drug appears to be superior to placebo and offers considerable promise for the treatment of this condition.
McGrath, Arnolda, Matthews, Jackson, Jennings, Kiat, Johnston congestive heart failure (New York Heart Association functional class II or III) participated in the study which was approved by the ethics committees of Prince Henry's and Prince Alfred's Hospitals. The cause of the heart failure was ischaemic heart disease in 18 (including one patient with an aortic valve replacement) and cardiomyopathy in seven (four idiopathic, three alcoholic).
To qualify for entry to the study, each patient gave informed consent and was stable on digoxin and frusemide. Their exercise capacity was limited to stage III, but was less than stage IX of an exercise test with a modified Naughton protocol. In addition, all patients had left ventricular ejection fractions less than 40%. General exclusions included patients with right sided heart failure due to pulmonary disease, surgically correctable aortic valve or congenital heart disease, recent unstable angina or myocardial infarction within the previous four months, and those in whom other antihypertensive agents, potassium sparing diuretics, inotropes, or vasodilators could not be withdrawn. Once the study entry criteria had been satisfied, the patients were required to remain clinically stable for two weeks on the same doses of digoxin and frusemide. Before entry into the study 19 patients had been receiving other vasodilator therapy (hydralazine, prazosin). This therapy was discontinued for at least two weeks before the start of study. Ten patients had also been receiving long acting nitrates which were withdrawn in seven, but in three patients nitrate paste was continued to control angina. The same dose was used throughout the trial for these three patients, two of whom were assigned to the enalapril group and one to the placebo group. Potassium supplements were discontinued in the week before the trial started. Patients were randomised in a double blind manner to receive, in addition to the previous doses of digoxin and frusemide, either enalapril 5 (9) 123 (7) 121(6) 11 1 (7)* Diastolic 70 (5) 71 (4) 70 (4) 63 (4)* Pulse rate (beats/min) 93 (7) 87 (6) 85 (6) 76 (4)* Plasma ACE activity (nmol/ml/min) 39 (5) 38 (4) 32 (4) 20 (3)*** Plasma angiotensin II (pg/ml) 35 (10) 33 (10) 72 (20) 30 (10)** Plasma renin (ng/ml/h) 17 (4) 7 (1)* 31 (10) 40 (11) Plasma catecholamines (pmol/ml): Symptoms improved in the enalapril treated group whereas the placebo treated group showed a deterioration. This was shown by an analysis of the changes in fatigue, breathlessness, and New York Heart Association functional class over 12 weeks of treatment (Table 3 ). In the placebo group seven of 12 patients had worsening of heart failure with a change to a higher New York functional class and five of these patients had to be withdrawn from the trial. All five had progressed to functional class IV and required changes in their treatment to control symptoms. Of the 13 patients in the active treatment group, two patients were withdrawn, one after 4 weeks because of worsening heart failure and one 1 Changes in supine blood pressure, plasma angiotensin converting enzyme activity (ACE), and plasma angiotensin II concentrations after the first dose (4 hours) and during long term treatment (4 weeks) with placebo (n = 8) or enalapril (n = 10). *p < 0 05, **p < 0-01, ***p < 0 001 compared with pretreatment result. HL, histidyl-leucine. (Table 4) . Before treatment (week 0) plasma noradrenaline concentrations increased progressively in response to increasing workload and the changes were similar in the placebo and enalapril groups ( converting enzyme activity at week 4 was 94(6)% (n = 8) and at week 12 it was 92(9)% (n = 5). In eight patients in the enalapril group, treatment for two weeks resulted in plasma enalaprilate concentrations of 33(4)% ng/ml and a reduction in converting enzyme activity to 82(5)%. After four weeks the results were similar (enalaprilate 32(3) ng/ml; angiotensin converting enzyme activity 83(4)% of control values). In five of these patients the dose of enalapril was increased to 10 mg twice daily. After two and four weeks this resulted in increased concentrations of plasma enalaprilate (56(5), 66(8) ng/ml) and greater angiotensin converting enzyme inhibition (61(5), 67(6)% of control values). Plasma concentrations of enalaprilate showed a significant linear correlation with plasma angiotensin converting enzyme activity (r= -066, n=41, p<0001). The analysis showed that there was a clear separation in the responses to the two dose regimens used (Fig. 2) . 
CREATININE
There were significant differences between the groups for changes in plasma concentrations of potassium and creatinine (Fig. 3) . The placebo 411 treated group showed no significant changes in either plasma potassium or creatinine concentrations. In the enalapril treated group there was a significant rise in plasma potassium (F660= 2-98, p <0 025). This was evident by two weeks and the increase was maintained for the duration of treatment. A slight rise in plasma creatinine was also observed (F6,60 = 249, p < 0 05), the maximum change being observed after six weeks of treatment (167(25) vs 138 (12) pmol/l, n=11, t=-1-79, p< 010).
There were no significant changes in haemoglobin, white blood cell count, or platelet count in either group over the 12 weeks of observation.
Discussion
The results of this study suggest that enalapril is superior to placebo when added to digoxin and diuretic therapy in patients with moderate to severe heart failure. There was an improvement in the symptoms of fatigue and shortness of breath in most enalapril treated patients but in only one of the 12 placebo treated patients. There was also a significant difference between the groups for the numbers of patients who had worsening heart failure as assessed by a change in their New York Heart Association functional class (1/13 (8%) of the enalapil group versus 7/12 (58%) of the placebo group).
In this study the clinical improvement in enalapril treated patients occurred without any significant changes in exercise duration or cardiac ejection fraction. This contrasts with a recent trial in which an increase in both of these measurements was reported after 12 weeks in enalapril treated but not in placebo treated patients. 27 The design of that study, however, was different because diuretic therapy was varied according to symptoms 37 and in accord with the results of other studies of captopril in cardiac failure. " The importance of having a placebo control group when examining these hormonal responses is emphasised by examining the acute changes in plasma renin and noradrenaline ( Table 2 ). In the placebo group there were reductions in plasma renin and noradrenaline concentrations although only the plasma renin changes were significant. These changes would be consistent with prolonged rest.
An advantage of angiotensin converting enzyme inhibitors is their ability to block secondary hyperaldosteronism and thus maintain normal serum potassium concentrations particularly in the face of potent diuretic therapy. This has been noted with captopril therapy in patients with hypertension38 and cardiac failure. In the present study there was a significant increase in plasma potassium in the enalapril treated group; no change occurred in the placebo group. None of the patients was receiving potassium supplements or potassium sparing diuretics, both of which had been discontinued before entry to the study.
A potential disadvantage of angiotensin converting enzyme inhibitors is that they may impair renal glomerular function by reducing efferent arteriolar resistance via inhibition of intrarenal angiotensin II formation. Patients 
